Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Articles|February 1, 1999
- Psychiatric Times Vol 16 No 2
- Volume 16
- Issue 2
Woman With a Finger Stuck in Her Nose
Woman With a Finger Stuck in Her Nose - Poetry of the Times
Advertisement
What was funny
wasn't where it was stuck,
or her phoning
Please, a surgeon,
my brain is leaking out!
No, the funny part was
the hospital operator
triaging her right
to psychiatry.
It's comical, too
when you get your own
finger stuck somewhere
and your brain starts to ooze,
how someone lands
from out of the blue
with a cork,
some suture,
or a few words
that hold you together
like crazy glue,
solid as a kiss,
a joke,
a prayer.
© CME LLC
2/99
Read more
of Dr. Berlin's work.
Articles in this issue
over 27 years ago
Chavez Warns of Declining Mental Health Resourcesover 27 years ago
Commentary: Kevorkian on Trialover 27 years ago
The Politics of Health Care Can the APA Make a Difference?over 27 years ago
National Center for Alternative Medicine Establishedover 27 years ago
Scientific Assessment of Alternative Medicineover 27 years ago
Biofeedback and Anxietyover 27 years ago
Music Therapy for Inpatient Psychiatric Care in the 1990sover 27 years ago
Culture and Eating Disordersover 27 years ago
Therapeutic Aspects of the Human-Companion Animal InteractionAdvertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
5